Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 29:20:100885.
doi: 10.1016/j.ajpc.2024.100885. eCollection 2024 Dec.

Lipoprotein(a) throughout life in women

Pablo Corral  1 , María Gabriela Matta  1   2 , Carlos Aguilar-Salinas  3   4 , Roopa Mehta  5 , Gabriela Berg  6 , Massimiliano Ruscica  7   8 , Laura Schreier  6
Affiliations
Review

Lipoprotein(a) throughout life in women

Pablo Corral et al. Am J Prev Cardiol. .

Abstract

Lipoprotein (a) [Lp(a)] is a lipoprotein with multiple deleterious characteristics and is a recognized cardiovascular (CV) risk factor. The pro-atherogenic, pro-thrombotic, and pro-inflammatory features of Lp(a) are associated not only with atherosclerotic vascular disease but also with aortic valve calcification and all-cause mortality. One of the most interesting aspects of Lp(a) is that its level is determined by genetics in more than 90% of cases, with lifestyle habits having very little influence. Therefore, the recommendation is to test it, at least, once in a lifetime. Contrary to previous beliefs, evidence in recent decades has shown that women have the same or even greater CV risk than men of the same age, attributed to female sex hormones. Different stages of a woman's life can impact on Lp(a) levels, from newborn to menopause, including other critical moments such as menarche and pregnancy. The main objective of this review is to describe and analyze the effect of different specific periods of a woman's life on Lp(a) levels and the potential clinical relevance on their CV risk.

Keywords: Lipoprotein(a); Lipoprotein(a) variability; Women.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest concerning the preparation and submission of this manuscript.

Figures

Image, graphical abstract
Graphical abstract
See this image and copyright information in PMC

References

    1. Berg K., Mohr J. Genetics of the LP system. Acta Genet Stat Med. 1963;13:349–360. doi: 10.1159/000151818. - DOI - PubMed
    1. DeFilippis A.P., Trainor P.J., Thanassoulis G., Brumback L.C., Post W.S., Tsai M.Y., Tsimikas S. Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. Eur Heart J. 2022;43(10):971–981. doi: 10.1093/eurheartj/ehab600. Mar 7. - DOI - PMC - PubMed
    1. Tada H., Yamagami K., Sakata K., Usui S., Kawashiri M.A., Takamura M. Healthy lifestyle, lipoprotein(a) levels and the risk of coronary artery disease. Eur. J. Clin. Investig. 2024;54(1):e14093. doi: 10.1111/eci.14093. JanEpub 2023 Sep 15. - DOI - PubMed
    1. Reyes-Soffer G., Yeang C., Michos E.D., Boatwright W., Ballantyne C.M. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024;18 doi: 10.1016/j.ajpc.2024.100651. - DOI - PMC - PubMed
    1. Koschinsky M.L., Bajaj A., Boffa M.B., Dixon D.L., Ferdinand K.C., Gidding S.S., Gill E.A., Jacobson T.A., Michos E.D., Safarova M.S., Soffer D.E., Taub P.R., Wilkinson M.J., Wilson D.P., Ballantyne C.M. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 doi: 10.1016/j.jacl.2024.03.001. Mar 29:S1933-2874(24)00033-3. - DOI - PubMed